Mr Tomasz Kaczyński > Domanski Zakrzewski Palinka > Warsaw, Poland > Lawyer Profile

Domanski Zakrzewski Palinka
RONDO ONZ 1
00-124 WARSZAWA
Poland

Work Department

Life Sciences

Position

Partner in Life Sciences Practice. His expertise encompasses all areas of pharmaceutical law – product registration, reimbursement issues, manufacturing, distribution, parallel import, advertising law and clinical trial issues – he focuses particularly on creating distribution structure in the pharmaceutical market. Advises over 40 companies operating on the pharmaceutical market, including manufacturers, distributors and pharmacy chains. Specialises in food law, in particular regulations applicable to FSMP and dietary supplements. Advises clients on structuring distribution strategies, preventing antitrust agreements and abuse of dominant position, consumer protection law, and combating unfair competition. His experience also includes advising clients on the feed market and GMO food regulation and participation in inspection proceedings on the agri- food market. Previously he worked on public health issues in local administrative authorities where he was responsible e.g. for restructuring public health care centres in Mazowieckie Voivodship.

Languages

Polish and English

Memberships

Expert Council Member in the Polish Council for Supplements and Nutritional Foods (KRSiO).
Member of the Regional Chamber of Legal Advisers in Warsaw.

Lawyer Rankings

Poland > Healthcare and life sciences

(Leading individuals)

Tomasz KaczyńskiDomanski Zakrzewski Palinka

At Domanski Zakrzewski Palinka, the workload is split equally between project-based, strategic advice and regulatory assistance, including reacting to imminent legislative changes. Many of the team’s key senior practitioners – including Michał Czarnuch and Marcin Matczak – are specialists in administrative law, operating primarily at its intersection with the pharmaceutical sector. Tomasz Kaczyński and Marcin Pieklak are noted for their expertise in product registration and reimbursement issues.